» Articles » PMID: 24045971

Escitalopram Block of HERG Potassium Channels

Overview
Specialty Pharmacology
Date 2013 Sep 19
PMID 24045971
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Escitalopram, a selective serotonin reuptake inhibitor, is the pharmacologically active S-enantiomer of the racemic mixture of RS-citalopram and is widely used in the treatment of depression. The effects of escitalopram and citalopram on the human ether-a-go-go-related gene (hERG) channels expressed in human embryonic kidney cells were investigated using voltage-clamp and Western blot analyses. Both drugs blocked hERG currents in a concentration-dependent manner with an IC50 value of 2.6 μM for escitalopram and an IC50 value of 3.2 μM for citalopram. The blocking of hERG by escitalopram was voltage-dependent, with a steep increase across the voltage range of channel activation. However, voltage independence was observed over the full range of activation. The blocking by escitalopram was frequency dependent. A rapid application of escitalopram induced a rapid and reversible blocking of the tail current of hERG. The extent of the blocking by escitalopram during the depolarizing pulse was less than that during the repolarizing pulse, suggesting that escitalopram has a high affinity for the open state of the hERG channel, with a relatively lower affinity for the inactivated state. Both escitalopram and citalopram produced a reduction of hERG channel protein trafficking to the plasma membrane but did not affect the short-term internalization of the hERG channel. These results suggest that escitalopram blocked hERG currents at a supratherapeutic concentration and that it did so by preferentially binding to both the open and the inactivated states of the channels and by inhibiting the trafficking of hERG channel protein to the plasma membrane.

Citing Articles

Cardiovascular adverse reactions associated with escitalopram in patients with underlying cardiovascular diseases: a systematic review and meta-analysis.

Kimura K, Narita H, Imai H, Akiyama H, Ishikawa S, Sawagashira R Front Psychiatry. 2023; 14:1248397.

PMID: 37810602 PMC: 10556499. DOI: 10.3389/fpsyt.2023.1248397.


The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study.

Assimon M, Pun P, Al-Khatib S, Brookhart M, Gaynes B, Winkelmayer W Nephrol Dial Transplant. 2022; 37(11):2241-2252.

PMID: 35793567 PMC: 9585464. DOI: 10.1093/ndt/gfac214.


Risk of out-of-hospital cardiac arrest in antidepressant drug users.

Eroglu T, Barcella C, Gerds T, Kessing L, Zylyftari N, Mohr G Br J Clin Pharmacol. 2022; 88(7):3162-3171.

PMID: 35001414 PMC: 9303588. DOI: 10.1111/bcp.15224.


Cardiac hERG K Channel as Safety and Pharmacological Target.

Su S, Sun J, Wang Y, Xu Y Handb Exp Pharmacol. 2021; 267:139-166.

PMID: 33829343 DOI: 10.1007/164_2021_455.


Selective serotonin reuptake inhibitor escitalopram inhibits 5-HT receptor currents in NCB-20 cells.

Park Y, Sung K Korean J Physiol Pharmacol. 2019; 23(6):509-517.

PMID: 31680773 PMC: 6819908. DOI: 10.4196/kjpp.2019.23.6.509.


References
1.
Dennis A, Nassal D, Deschenes I, Thomas D, Ficker E . Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG. J Biol Chem. 2011; 286(39):34413-25. PMC: 3190784. DOI: 10.1074/jbc.M111.254367. View

2.
Melzacka M, Rurak A, Adamus A, Daniel W . Distribution of citalopram in the blood serum and in the central nervous system of rats after single and multiple dosage. Pol J Pharmacol Pharm. 1984; 36(6):675-82. View

3.
Waugh J, Goa K . Escitalopram : a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003; 17(5):343-62. DOI: 10.2165/00023210-200317050-00004. View

4.
Yang M, Sim S, Jeon J, Jeong E, Kim H, Park Y . Mitral and tufted cells are potential cellular targets of nitration in the olfactory bulb of aged mice. PLoS One. 2013; 8(3):e59673. PMC: 3601056. DOI: 10.1371/journal.pone.0059673. View

5.
Fayssoil A, Issi J, Guerbaa M, Raynaud J, Heroguelle V . Torsade de pointes induced by citalopram and amiodarone. Ann Cardiol Angeiol (Paris). 2011; 60(3):165-8. DOI: 10.1016/j.ancard.2010.12.002. View